• Clinical Trials - Liver cancer

    Study Objective Contact
    A Humanitarian Device Exemption Treatment Protocol Of Therasphere® For Treatment Of Unresectable Hepatocellular Carcinoma [LCID Study Number: 2009-043] Protocol Of Therasphere® For Treatment Of Unresectable Hepatocellular Carcinoma. TheraSphere is a low toxicity, targeted liver cancer therapy that consists of millions of tiny radiosactive glass beads about a third of the width of a human hair that are delivered directly to liver tumors. Principal Investigator(s):
    Sebastian Flacke, MD, PhD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Nanette Matrullo.
    A Phase III Clinical Trial Evaluating Therasphere® in Patients with Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy (TS102-EPOCH) [LCID Study Number: 2012-048] The effectiveness and safety of TheraSphere will be evaluated in patients with colorectal cancer with metastases in the liver, who are scheduled to receive second line chemotherapy. All patients receive the standard of care chemotherapy with or without the addition of TheraSphere. Principal Investigator(s):
    Shams I. Iqbal, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Nanette Matrullo.
    A Randomized Phase II Study of Individualized Stereotactic Body Radiation Therapy (SBRT) versus Trans-Arterial Chemoembolization (TACE) with DEBDOX Beads as a Bridge to Transplant in Hepatocellular Carcinoma. [LCID Study Number: 2014-026] Patients undergoing treatment will be imaged by MRI or triphasic CT every three months following therapy using mRECIST criteria. Any tumors meeting radiologic criteria for residual tumor or tumor progression will undergo repeat treatment with the modality first utilized unless such treatment is not possible. The time to first retreatment will be measured and compared between treatment arms using cumulative incidence curves to account for the competing risks of transplant, death, and stop of treatment before re-treatment. Principal Investigator(s):
    Francis W. Nugent, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Erin H. Hartnett.
    Molecular Analysis of Cancer [LCID Study Number: 2011-048] The purpose of this research is to discover molecular changes involved in cancer. We hope that a better understanding of these changes can improve cancer management. This research may include genetic and/or genomic analysis (tests to determine and compare your genetic sequence, or DNA). Some of the tissue we collect for our research may be submitted to the National Cancer Institute Cancer Genome Atlas Project. The goal of this project is to determine the genomic changes involved in more than 20 types of human cancer. Principal Investigator(s):
    Kimberly R. Christ, PhD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Doreen L. Browne, ,CCRP,
    Jane S. Nalwalk,
    Linda M. Topjian.